Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer
Launched by EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - EORTC · Jan 26, 2003
Trial Information
Current as of March 20, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Compare time to recurrence and survival of patients with single, low stage, nonmetastatic, well localized, and well delineated renal cell cancer treated with partial vs radical resection.
* Establish the side effects of kidney-sparing tumor resection in terms of morbidity and mortality in these patients.
* Study the relationship between tumor size, histologic grade, histologic type, and the extent of local control following partial resection.
* Determine which prognostic factors are important in selecting candidates for conservative surgery.
OUTLINE: This is a randomized, mu...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- * Single renal T1-2 tumor suspicious for adenocarcinoma that meets the following requirements:
- • Solitary tumor on CT scan
- • Maximum diameter 5 cm
- • Located such that negative resection margins are assured
- • N0, M0, i.e., no nodal involvement or distant metastases
- • No invasion of renal pelvis, calices, or perirenal fat as determined by CT scan or intravenous urography
- • Normal contralateral kidney present
- • No von Hippel-Lindau disease
- PATIENT CHARACTERISTICS:
- Age:
- • Any age
- Performance status:
- • WHO 0-2
- Hematopoietic:
- • Not specified
- Hepatic:
- • Not specified
- Renal:
- • Not specified
- Other:
- • No second malignancy except adequately treated nonmelanomatous skin cancer
- PRIOR CONCURRENT THERAPY:
- • Biologic therapy
- • Not specified
- • Chemotherapy
- • Not specified
- • Endocrine therapy
- • Not specified
- • Radiotherapy
- • Not specified
- • Surgery
- • Not specified
Trial Officials
Hein van Poppel, MD, PhD
Study Chair
University Hospital, Gasthuisberg
Thomas Keane, MD
Study Chair
Emory University
Leonard G. Gomella, MD
Study Chair
Sidney Kimmel Cancer Center at Thomas Jefferson University
Eila C. Skinner, MD
Study Chair
University of Southern California
Laurence H. Klotz, MD
Study Chair
Toronto Sunnybrook Regional Cancer Centre
About European Organisation For Research And Treatment Of Cancer Eortc
The European Organisation for Research and Treatment of Cancer (EORTC) is a prominent non-profit organization dedicated to advancing cancer research and improving patient care through innovative clinical trials. Established in 1962, EORTC fosters collaboration among international researchers, healthcare professionals, and institutions to develop and implement rigorous clinical studies that evaluate novel therapies and treatment strategies. With a strong commitment to enhancing the quality of life for cancer patients, EORTC focuses on multidisciplinary approaches and the integration of patient-reported outcomes, ensuring that its findings translate effectively into clinical practice and contribute to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
North York, Ontario, Canada
Montreal, Quebec, Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials